Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4R-Fluoro-N6-ethanimidoyl-L-lysine is a synthetic small molecule analog of L-lysine, specifically designed as a selective inhibitor of inducible nitric oxide synthase (iNOS). The compound features a fluorinated modification at the 4-position and an ethanimidoyl group at the N6 position. It has been studied for its potential to selectively inhibit iNOS activity, which may be relevant in conditions where excessive nitric oxide production contributes to pathology. The compound is considered experimental and has not been approved for any clinical indications[1][5][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4R-Fluoro-N6-ethanimidoyl-L-lysine.